FT Global Pharmaceutical and Biotechnology Conference London

The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to care, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, health treatment and services.

The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends from biosimilars, to digital therapeutics to next generation neuroscience and diagnostics set to reshape the industry far into the future.